Emergent Biosolutions EBS Accounts Payable

Accounts Payable at other companies

Regeneron PharmaceuticalsREGN

$1.16B+60.1%

SIGA TechnologiesSIGA

$909.83K-23.7%

AMP

Amphastar PharmaceuticalsAMPH

$251.37M+50.9%

Lifecore Biomedical, Inc.LFCR

$7.53M—

Rapid Micro BiosystemsRPID

$5.18M+55.3%

Cumberland PharmaceuticalsCPIX

$19.55M+45.4%

FAQ

What is Emergent Biosolutions's accounts payable?

Emergent Biosolutions (EBS) reported accounts payable of $50.2M in Q2 2026.

How has Emergent Biosolutions's accounts payable changed year-over-year?

Emergent Biosolutions's accounts payable decreased by 21.2% year-over-year, from $63.7M to $50.2M.

What is the long-term trend for Emergent Biosolutions's accounts payable?

Over 5 years (2020 to 2025), Emergent Biosolutions's accounts payable has grown at a -16.4% compound annual growth rate (CAGR), from $136.1M to $55.6M.

What does accounts payable mean?

Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.